Disruptive Pharma raises 27 million SEK to conduct clinical study on its improved sorafenib product DPH001 and to nominate second product candidate

On April 26, 2024 Disruptive Pharma reported the company raises 27 million SEK to conduct clinical study on its improved sorafenib product DPH001 and to nominate second product candidate (Press release, Disruptive Pharma, APR 26, 2024, View Source [SID1234649946]). The company also reported we now have sufficient funds to advanced our innovative first product DPH001 through clinical proof-of-concept and nominating a second product candidate within the next 12 months, thus transforming Disruptive Pharma from a research company into a clinical stage pharmaceutical company. I want to extend a warm thank you to all long-term shareholders and new investors for your trust." comments Peter Åsberg, CEO of Disruptive Pharma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!